FDA OKs Revlimid as Maintenance Therapy in Multiple Myeloma Auto-HSCT Patients
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple myeloma patients who received an…
News
Myeloma Patients Treated at High-volume Facilities Have Lower Risk of Death, Study Finds
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at lower-volume facilities, according to recent…
First Myeloma Patient Joins Trial of Therapy for Cancers That Failed to Respond to Treatment
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have failed to respond to treatment.
Artist Will Donate Part of Proceeds from Hollyweed T-shirt Sales to Myeloma
A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization of recreational marijuana — and…
Patients with Indolent Myeloma Don’t Benefit from ICAM1 Inhibitor, Trial Results Show
Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
Phase 1 Trial to Assess Safety of Radioactive Anti-CD33 Antibody in Advanced Myeloma
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
Patients Value Obamacare More Than General Public and Oppose Its Repeal, Survey Says
People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey by PatientsLikeMe has found. They are also…
Natural Killer Cells Could Be Used to Treat Myeloma, Small Study Suggests
A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…
ASCT Benefited Younger, Older Multiple Myeloma Patients Equally, Study Finds
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.
Alkeran-based 4-drug Combo Gives Excellent Outcomes in Myeloma Patients Undergoing Transplants
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL